Abstract 45P
Background
CD73 contributes to immune evasion in solid tumors by producing immune-suppressive adenosine in the tumor microenvironment. Herein, we describe CBO-212, a first-in-class CD73 targeting DFC, comprising a multi-valent conjugate of a novel small molecule CD73 inhibitor to a proprietary immune-silent hIgG1 Fc. CBO-212 combines the strengths of small molecule inhibitors and monoclonal antibodies targeting CD73 currently in clinical development with potential best-in-class activity.
Methods
Inhibition of CD73 was evaluated in cell-free and cell-based assays. Functional activity was measured in a PBMC rescue assay in the presence of AMP and binding to cancer cells was measured in the presence and absence of AMP by flow cytometry. CD73 internalization was determined using MDA-MB-231 cells. Pharmacokinetic (PK) studies were conducted in Balb/c mice. Plasma concentrations were measured using an anti-hIgG in combination with CD73 capture ELISA. Efficacy of CBO-212 was evaluated in syngeneic mouse models with established CT26.WT tumors.
Results
CBO-212 is a potent, AMP-competitive CD73 inhibitor. In cell-free and cell-based CD73 inhibition assays, CBO-212 IC50s were single digit nM, making them comparable or superior to small molecule inhibitors and anti-CD73 mAbs in clinical development. Unlike most anti-CD73 mAbs, CBO-212 demonstrated complete enzyme inhibition. Furthermore, CBO-212 demonstrated an EC50 in a human PBMC rescue assay of 6 nM, which was equivalent to small molecule inhibitor controls and approximately 100-fold more potent than anti-CD73 mAb controls. Additionally, CBO-212 triggered CD73 internalization, similar to some anti-CD73 mAbs. CBO-212 demonstrates long half-life and stability in mice. In a syngeneic mouse colon cancer model, a single 20 mg/kg dose of CBO-212 resulted in 37.9% tumor growth inhibition (TGI) relative to vehicle (P=0.0152).
Conclusions
CBO-212 demonstrated high potency in CD73 enzyme inhibition and functional PBMC rescue assays. The in vitro potency and favorable PK of CBO-212 translated to significant TGI in a syngeneic model with a single dose. Based on these results CBO-212 is being advanced as a clinical development candidate for the treatment of solid cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cidara Therapeutics.
Funding
Cidara Therapeutics.
Disclosure
J. Levin, S. Döhrmann, N. Dedeic, A. Almaguer, D. Zuill, E. Abelovski, R. Grewal, J. Fortier, Q. Zhao, M. Hernandez, K. Amundson, M. Moniz, H. Chen, D. Panickar, T. Lam, T. Brady, A. Borchardt: Financial Interests, Personal, Full or part-time Employment, Shareholder: Cidara Therapeutics.
Resources from the same session
2P - SOT102, a novel CLDN18.2-targeting antibody-drug conjugate for gastric and pancreatic cancer with a wide range of the tumor target expression
Presenter: Radek Spisek
Session: Cocktail & Poster Display session
Resources:
Abstract
3P - Correlation between antibody-drug conjugate (ADC) targetable antigen expression and occurrence of interstitial lung disease (ILD)
Presenter: Solange Peters
Session: Cocktail & Poster Display session
Resources:
Abstract
4P - Optimizing utilization of antibody-drug conjugates in NSCLC by identification of subsets using RNA sequencing
Presenter: Edwin Lin
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations
Presenter: Jenna Voellinger
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - RC48-ADC for metastatic salivary duct carcinoma with HER2 expression: A single-center retrospective study
Presenter: jun Cao
Session: Cocktail & Poster Display session
Resources:
Abstract
7P - Global ring study determining reproducibility & comparability of CLDN18 testing assays in gastric cancer
Presenter: Bharat Jasani
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Targeting antiapoptotic Bcl-2 proteins with highly specific BH3 mimetics in solid tumors
Presenter: Benjamin Sobol
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - An in vivo model for therapeutic antibody efficacy evaluation: The chicken embryo’s CAM-based assay
Presenter: Yan Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Successful transfer and prolonged persistence of engineered lymphocytes with T-cell receptor targeting NY-ESO-1
Presenter: Johnathan Arnon
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - CRISPR/Cas9-induced knock-out of DGKαζ in TAG-72 CAR-T cells improves function and persistence in ovarian cancer
Presenter: Vera Evtimov
Session: Cocktail & Poster Display session
Resources:
Abstract